Drug-eluting stents reduce restenosis rates and major adverse cardiac events, but not mortality, in patients undergoing percutaneous coronary intervention

World Health Organization. Atlas of Heart Disease and Stroke. Available at: http://www.who.int/cardiovascular_diseases/resources/atlas/en Windecker S, Meier B, Meyer BJ, for the Working Group on Coronary Circulation. Interventional Cardiology in Europe: Trends from 1992 to 1995. Circulation 1997; 96: 1–148. Bittl, 1996, Advances in coronary angioplasty, N Engl J Med, 335, 1290, 10.1056/NEJM199610243351707 Dussaillant, 1995, Small stent size and intimal hyperplasia contribute to restenosis, J Am Coll Cardiol, 26, 720, 10.1016/0735-1097(95)00249-4 Hoffmann, 1996, Patterns and mechanisms of in-stent restenosis, Circulation, 94, 1247, 10.1161/01.CIR.94.6.1247 Serruys, 2001, Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease, N Engl J Med, 344, 1117, 10.1056/NEJM200104123441502 Kong, 1999, Steroids for restenosis, Am Heart J, 138, 3, 10.1016/S0002-8703(99)70234-6 Babapulle, 2004, A hierarchical Bayesian meta-analysis of randomized clinical trials of drug-eluting stents, Lancet, 364, 583, 10.1016/S0140-6736(04)16850-5 Mark, 2003, Medical Economics in Interventional Cardiology Federal Register. Medicare Program; Changes to the Hospital Outpatient Prospective Payment System. August 9, 2002;67: 50003–50005. Available at wais.access.gpo.gov.